




	<b>EMLc</b>	ATC codes: <b>V03AF01</b>
<b>Indication</b>	Osteosarcoma of bone and articular cartilage of other specified sites ICD11 code: <b>2C21.Y</b>	
<b>INN</b>	Mesna	
<b>Medicine type</b>	Chemical agent	
<b>List type</b>	Complementary (EML) (EMLc)	
<b>Formulations</b>	Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule ; 100 mg per mL in 10 mL ampoule Oral > Solid: 400 mg ; 600 mg	
<b>EML status history</b>	First added in 2015 ( <b>TRS 994</b> )	
<b>Sex</b>	All	
<b>Age</b>	Also recommended for children	
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine	
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 	
<b>Tags</b>	<span style="background-color: #ff69b4; border-radius: 15px; padding: 2px 10px;">Cancer</span>	
<b>Wikipedia</b>	<a href="#">Mesna</a> 	
<b>DrugBank</b>	<a href="#">Mesna (Coenzyme M)</a> 	

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for mesna on the complementary list of the EML and EMLc for use in treatment protocols for osteosarcoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for osteosarcoma is attached.

[Expert Committee report](#) 

